NDAORALCAPSULE
Approved
Sep 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
1
Mechanism of Action
Glucosylceramide Synthase Inhibitors
Pharmacologic Class:
Glucosylceramide Synthase Inhibitor
Clinical Trials (1)
A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18
Started Jul 2023
Loss of Exclusivity
LOE Date
Sep 16, 2038
152 months away
Patent Expiry
Sep 16, 2038
Exclusivity Expiry
Sep 28, 2026